Biontech (BNTX) Akcija Kursas
Biontech Kursas
Pajamos augo 61,0 % per metus per pastaruosius 8 metus iki 3,17 mlrd. EUR. Pelnas akcijai augo 296,1 % per metus per pastaruosius 3 metus. Biontech grynoji marža dabar yra −39,8 %, sumažėjo nuo 54,3 % prieš kelerius metus. Biontech šiuo metu siūlo apie 2,71 % dividendo pajamingumą. Išmokų koeficientas yra apie 4 % pelno. Analitikų tikslinės kainos mediana yra 120,97 EUR, t. y. virš dabartinę kainą 53,9 %. Iš 29 analitikų 20 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Biontech akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Biontech akcija ir akcijų analizė
Dažnai užduodami klausimai apie Biontech akciją
BioNTech SE is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of BioNTech SE in the market include other leading biotechnology companies such as Moderna Inc., Johnson & Johnson, Pfizer Inc., Novavax Inc., and AstraZeneca Plc. These companies operate in the same space, focusing on developing novel therapeutics and vaccines to address various diseases and medical conditions. BioNTech SE actively competes with these organizations in the field of mRNA technology and immunotherapy to advance medical innovations and improve patient outcomes.
The business model of BioNTech SE revolves around the development and commercialization of transformative therapies for cancer and other serious diseases. The company specializes in individualized immunotherapies and utilizes its proprietary mRNA technology platform to harness the body's immune system to fight against diseases. BioNTech collaborates with various pharmaceutical partners to advance its programs and conduct clinical trials. By leveraging its expertise in mRNA and immunotherapy, BioNTech aims to deliver innovative treatment options to patients worldwide. Through its commitment to research, development, and strategic partnerships, BioNTech strives to shape the future of medicine with its groundbreaking therapies.
BioNTech SE is a biotechnology company founded in 2008 by Özlem Türeci and Uğur Şahin in Mainz, Germany. The company specializes in the development of personalized cancer immunotherapies and individualized mRNA-based drugs. BioNTech became widely recognized for its pivotal role in developing the mRNA-based Pfizer-BioNTech COVID-19 vaccine. With a strong focus on research and development, BioNTech has built a reputation for its innovative approach to tackling various diseases, including cancer and infectious diseases. As a pioneer in mRNA technology, BioNTech continues to drive advancements in the field of precision medicine, leading the way in the fight against diseases worldwide.
BioNTech SE, a renowned biotechnology company, has achieved significant milestones over the years. Notably, the company successfully developed and gained regulatory approval for its mRNA-based COVID-19 vaccine, in collaboration with Pfizer. This groundbreaking achievement positioned BioNTech as a key player in the global fight against the pandemic. Additionally, BioNTech has made remarkable progress in advancing personalized cancer immunotherapy through the development of individualized mRNA-based cancer vaccines. The company's continuous innovation, partnerships, and successful clinical trials have propelled BioNTech into the forefront of the biotech industry and solidified its position as a leading pioneer in mRNA technology.
BioNTech SE, a leading biotechnology company, operates globally to foster breakthrough advancements in immunotherapies for cancer and infectious diseases. The company has a strong international presence and operates primarily in various countries and regions worldwide. BioNTech SE's key operations extend across the United States, Germany, China, and Singapore, among other strategic locations. By collaborating with renowned partners and establishing a robust network, BioNTech SE aims to accelerate the development and commercialization of innovative therapies, contributing to the improvement of global healthcare.
BioNTech SE represents values of innovation, collaboration, and dedication to improving global health. The company's corporate philosophy is centered around leveraging cutting-edge technology and scientific expertise to develop transformative therapies for patients worldwide. BioNTech is committed to delivering groundbreaking solutions in the field of immunotherapy, particularly in the areas of precision cancer medicine and personalized medicine. With its pioneering mRNA technology platform, BioNTech aims to revolutionize how diseases are treated and prevented, ultimately leading to a future where individualized medicine becomes the norm. The company's unwavering commitment to excellence, scientific rigor, and patient-centric approach defines its core values and drives its mission forward.
Analitikai šiuo metu nustato vidutinę Biontech akcijos tikslinę kainą 116,87 EUR (mediana: 120,97 EUR), t. y. +48,7 % palyginti su paskutine kaina. Konsensusas pagrįstas 29 analitikų reitingais.
29 analitikai šiuo metu vertina Biontech akciją: 20 rekomenduoja pirkti, 9 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Biontech gaus 1,80 mlrd. EUR pajamų ir −5,33 EUR pelno akcijai.
Biontech akcija (BNTX) kotiruojama 12 biržose, įskaitant: NYSE (BNTX), London (0A3M.L), SIX (Zürich) (22UA.SW), XETRA (22UA.DE), Frankfurt (22UA.F), München (22UA.MU), Düsseldorf (22UA.DU), Berlin (22UA.BE).
BioNTech SE is a German biotechnology company that was founded in 2008 and is headquartered in Mainz. It focuses on the development and production of personalized immunoncological medications for the treatment of cancer and infectious diseases. The company's business model is designed for several sectors. On one hand, BioNTech collaborates with the industry to develop customized therapeutics based on mRNA technology. On the other hand, the company utilizes its expertise to research its own medications, which are marketed in collaboration with external partners. The fundamental principle of mRNA technology at BioNTech is the development of personalized therapeutics that take into account the patient's individual genetic makeup. Specific antigens of the respective tumor are identified and corresponding mRNA molecules are produced. These are then injected into the patient's body to trigger a targeted immune response against the cancer cells. Personalizing the treatment increases its effectiveness and tolerability. BioNTech also pursues various production methods. The production of GMP-compliant mRNA active substances (GMP – Good Manufacturing Practice) is an important focus of the company. For this purpose, BioNTech has established its own production facility in Mainz, which started operating in May 2020 and has high capacities. This production facility is one of the largest mRNA production centers in Europe and is equipped with modern cleanrooms and highly efficient technologies. Product development at BioNTech ranges from preclinical research to clinical studies and drug approval. The company plays a pioneering role in this field and has entered into numerous collaborations with partners in the biopharmaceutical industry. BioNTech also operates several independent products, with a focus on cancer immunotherapy. The company has developed BNT111, a clinical phase I product for the treatment of late-stage tumors. In this case, a specific antigen present on cancer cells is recognized and fought by T cells. In collaboration with the US pharmaceutical company Pfizer, BioNTech has also developed a COVID-19 vaccine. The vaccine is one of the first mRNA-based COVID-19 vaccines approved by the U.S. Food and Drug Administration (FDA). With the COVID-19 vaccine, BioNTech has made a significant contribution to the fight against the global pandemic. In summary, BioNTech is an innovative, research-driven biotechnology company that specializes in personalized cancer immunotherapy. The company has achieved a significant milestone in combating the COVID-19 pandemic in a short period of time and will continue to be an important player in the biopharmaceutical industry in the future.
tikėtina pelnas Biontech yra 1,80 mlrd. EUR. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Biontech yra −1,31 mlrd. EUR. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Biontech šiuo metu yra −14,75. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Biontech akcijos vertę.
Kainų ir pardavimų santykis (KUV) Biontech šiuo metu yra 10,69. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Biontech akcijos įvertinimo metrika.
Eulerpool kokybės balas Biontech yra 1/10.
Biontech ISIN yra US09075V1026. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Biontech WKN yra A2PSR2. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Biontech prekybos žymė yra BNTX. Ši biržos žymė naudojama Biontech akcijoms prekiauti biržoje.
Biontech akcija
Biontech Pagrindiniai konkurentai
Biontech Biržos simbolis
Biontech FIGI
Visos Biontech pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Biontech akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Biontech. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: